Skip to main content
Top

01-04-2024 | Glioblastoma | Original Article

The effect of indicators of CALLY index on survival in glioblastoma

Authors: Umut Ogün Mutlucan, Cihan Bedel, Fatih Selvi, Ökkeş Zortuk, Cezmi Çağrı Türk, Mustafa Korkut

Published in: Irish Journal of Medical Science (1971 -)

Login to get access

Abstract

Introduction

Glioblastoma is the most common primary brain tumor in adults. Recently, research has been published on the potential prognostic indicators associated with different types of cancer. Due to the limited availability of data investigating the relationship between the CALLY index and glioblastoma patients, we aimed to conduct this study.

Materials and methods

Between January 2017 and December 2023, we conducted a study on patients diagnosed with glioblastoma. We collected demographic data and routine laboratory tests at the time of admission. To calculate the CALLY index, we used the formula (albumin value × lymphocyte count) / CRP value × 104. Parameters were compared for in-hospital mortality across different groups.

Results

The study analyzed 202 patients who met the inclusion criteria. Of these, 165 (81.7%) were classified as “survivors” and 37 (18.3%) as “deceased.” A comparison of hematologic parameters between the two groups showed a significantly lower CALLY index in the “deceased” group (3.05 (4.92)) compared to the “survivor” group (10.13 (13.69)) (p < 0.001). The study compared the parameters between groups with regard to in-hospital mortality.

Conclusions

Based on the results of the study, we conclude that the CALLY index can be considered an easily applicable indicator for the mortality of glioblastoma patients.
Literature
19.
go back to reference Ha ET, Antonios JP, Soto H et al (2014) Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol Neuroinflammation 1(2):66–76CrossRef Ha ET, Antonios JP, Soto H et al (2014) Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol Neuroinflammation 1(2):66–76CrossRef
Metadata
Title
The effect of indicators of CALLY index on survival in glioblastoma
Authors
Umut Ogün Mutlucan
Cihan Bedel
Fatih Selvi
Ökkeş Zortuk
Cezmi Çağrı Türk
Mustafa Korkut
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-024-03666-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.